According to topline findings from the ongoing phase I/II ARROW trial:
- 61% of patients who were both treatment-naïve and received prior treatment with platinum-based chemotherapy, had their tumors shrunk or blocked along with robust evidence of activity against brain metastases
- Median duration of response to treatment has still not reached
- 73% of patients who received Pralsetinib, which is given orally once daily, as the first treatments had their tumors shrunk or blocked and 12% of them had Complete Remission of their disease
- Full findings of the trial are slated to be presented at an upcoming medical meeting.
Pralsetinib is known to be a potent and highly selective inhibitor of RET-possitive tumors. The agent was previously granted a breakthrough therapy designation by the FDA for the treatment of patients with RET+ NSCLC that progressed on platinum-based chemotherapy, as well as RET+ Medullary Thyroid Cancer, MTC, that requires systemic therapy and for which there are no acceptable alternative therapies.
In the phase I/II ARROW trial, all patients (n = 354) were treated with the proposed indicated dose of Pralsetinib, which is 400 mg once daily.
The safety findings with Pralsetinib were found to be consistent with what has been reported in prior studies. The drug was found to be well tolerated. A total 4% of patients discontinued Pralsetinib therapy due to treatment-related side effects.
Current status of Pralsetinib
The FDA has granted Breakthrough Therapy Designation to Pralsetinib for the treatment of RET+ NSCLC that has progressed following platinum-based chemotherapy, and RET-mutant MTC that requires systemic treatment and for which there are no acceptable alternative treatments.
About Non Small Cell Lung Cancer, NSCLC
The lungs are a double respiratory organ with a sponge-like texture and shaped like a cone in the chest. The lungs provide the body with oxygen and remove carbon dioxide from the body in the process of breathing.
For most patients with stage 4 metastatic lung cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease. The National Cancer Institute, NCI, highlights the fact that for a certain group of lung cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.
Contact us to find out what is the best treatment for YOU
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039